IL213214A0 - Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases - Google Patents

Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases

Info

Publication number
IL213214A0
IL213214A0 IL213214A IL21321411A IL213214A0 IL 213214 A0 IL213214 A0 IL 213214A0 IL 213214 A IL213214 A IL 213214A IL 21321411 A IL21321411 A IL 21321411A IL 213214 A0 IL213214 A0 IL 213214A0
Authority
IL
Israel
Prior art keywords
cilostazol
vascular
treatment
metabolic diseases
nitrate derivatives
Prior art date
Application number
IL213214A
Other languages
English (en)
Original Assignee
Cardiolynx Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiolynx Ag filed Critical Cardiolynx Ag
Publication of IL213214A0 publication Critical patent/IL213214A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL213214A 2008-12-02 2011-05-30 Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases IL213214A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170435A EP2194048A1 (en) 2008-12-02 2008-12-02 Nitrate esters for the treatment of vascular and metabolic diseases
PCT/EP2009/066159 WO2010063724A1 (en) 2008-12-02 2009-12-01 Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases

Publications (1)

Publication Number Publication Date
IL213214A0 true IL213214A0 (en) 2011-07-31

Family

ID=40456966

Family Applications (1)

Application Number Title Priority Date Filing Date
IL213214A IL213214A0 (en) 2008-12-02 2011-05-30 Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases

Country Status (14)

Country Link
US (1) US8426597B2 (enExample)
EP (2) EP2194048A1 (enExample)
JP (1) JP2012510502A (enExample)
KR (1) KR20110088598A (enExample)
CN (1) CN102245583A (enExample)
AU (1) AU2009324123A1 (enExample)
BR (1) BRPI0923300A2 (enExample)
CA (1) CA2745252A1 (enExample)
IL (1) IL213214A0 (enExample)
MX (1) MX2011005744A (enExample)
RU (1) RU2011126607A (enExample)
SG (1) SG171423A1 (enExample)
WO (1) WO2010063724A1 (enExample)
ZA (1) ZA201104011B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2796710A1 (en) 2010-04-19 2011-10-27 Cardiolynx Ag Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases
AR081268A1 (es) 2010-06-02 2012-07-18 Cardiolynx Ag Derivados de nitrato de pioglitazona
ES2822004T3 (es) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticuerpos contra quetiapina y uso de los mismos
TR201816416T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
ES2807902T3 (es) 2012-08-21 2021-02-24 Janssen Pharmaceutica Nv Anticuerpos para olanzapina y uso de los mismos
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
PL2888286T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
EP3415516B1 (en) 2012-08-21 2021-12-15 Janssen Pharmaceutica NV Haptens of risperidone and paliperidone
EP2888234B1 (en) 2012-08-21 2017-12-06 Janssen Pharmaceutica NV Haptens of aripiprazole and their use in immunoassays
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
EP3663316A1 (en) 2012-08-21 2020-06-10 Janssen Pharmaceutica NV Antibodies to aripiprazole and use thereof
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
US9304126B2 (en) 2012-08-21 2016-04-05 Janssen Pharmaceutica Nv Haptens of quetiapine
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
WO2014031630A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to paliperidone and use thereof
US9303041B2 (en) 2012-08-21 2016-04-05 Janssen Pharmaceutica Nv Haptens of olanzapine
WO2017106501A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
WO2017106508A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
CN114044766B (zh) * 2021-10-09 2022-12-27 张北北九食品检验技术有限公司 放射性同位素碳-14标记的呋虫胺和中间体及其制备方法和应用
CN120441542B (zh) * 2025-05-08 2025-09-30 安徽益普克医药科技发展有限公司 一种西洛他唑衍生物及其制备方法与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
US6148496A (en) 1999-04-09 2000-11-21 The Procter & Gamble Company Method for making a seamless apertured metal belt
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
JP2007500684A (ja) 2003-07-31 2007-01-18 ニコックス エス エイ 心臓血管疾患治療用のアンギオテンシン−ii受容体遮断薬としてのロサルタン、バルサルタン、カンデサルタン、テルミサルタン、エプロサルタンおよびオルメサルタンのニトロオキシ誘導体
WO2006079610A1 (en) * 2005-01-31 2006-08-03 Nicox S.A. Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
EP1922069A2 (en) * 2005-08-08 2008-05-21 Nitromed, Inc. Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use

Also Published As

Publication number Publication date
RU2011126607A (ru) 2013-01-10
SG171423A1 (en) 2011-07-28
WO2010063724A1 (en) 2010-06-10
US8426597B2 (en) 2013-04-23
BRPI0923300A2 (pt) 2019-07-16
US20110230520A1 (en) 2011-09-22
JP2012510502A (ja) 2012-05-10
EP2367803A1 (en) 2011-09-28
ZA201104011B (en) 2012-02-29
EP2194048A1 (en) 2010-06-09
CA2745252A1 (en) 2010-06-10
AU2009324123A1 (en) 2011-07-21
MX2011005744A (es) 2011-06-20
CN102245583A (zh) 2011-11-16
KR20110088598A (ko) 2011-08-03

Similar Documents

Publication Publication Date Title
ZA201104011B (en) Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
IL210856A0 (en) Combination therapy for the treatment of diabetes and related conditions
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
IL209282A (en) History of n-pipridine-3-yl-2-benzimidazole carboxamide and drugs containing it for the treatment of cardiovascular disease
PH12013500892A1 (en) Composition for use in the prevention and/or treatment of skin conditions and skin diseases
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
PL3208612T3 (pl) Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
IL210802A0 (en) Purin derivatives for use in the treatment of fab-related diseases
EP2318005A4 (en) NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE DISEASES
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
IL223286A0 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
IL201189A (en) Fluorization derivatifrone derivatives used as iron pellets in the treatment of neurodegenerative diseases, their preparation and their pharmaceutical preparations
PL2328417T3 (pl) Związki, kompozycje i sposoby leczenia chorób beta-amyloidowych i synukleinopatii
IL218143A0 (en) Substituted heterocyclic derivatives for the treatment of pain and epilepsy
IL240560A0 (en) Preparations and methods for tumor diagnosis and treatment
ZA201304822B (en) Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
SI2148667T1 (sl) Uporaba derivatov cikloheksanheksola pri zdravljenju okularnih bolezni
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
SI2234631T1 (sl) Spojine in postopki za zdravljenje ĺ˝ilne bolezni
GB0909297D0 (en) Composition for the treatment of skin conditions
IL213703A (en) Compounds for the treatment of pain and other diseases
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea